The advances of Exendin-4 used for the treatment of type 2 diabetes

Fudan University Journal of Medical Sciences

Volumn 37, Issue 6, 2010, Pages 738-741

  Zhou, Qiong ^a   Feng, Jiao ^b  

^a FUDAN UNIVERSITY   (China)

^b INSTITUTE OF METAL RESEARCH   (China)

Author keywords

Exendin 4; Glucagon like peptide 1; Mechanism; Type 2 diabetes

Indexed keywords

EID: 78650141531     PISSN: 16728467     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Yang WY, Lu JM, Weng JP, et al. Prevalence of diabetes among men and women in China[J]. N Engl J Med, 2010, 362 (12): 1090-1101.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in subjects with type 2 diabetes[J]. Lancet, 1998, 352(9 131): 837-853.
3. Barnett AH. Exenatide[J]. Drugs Today (Bare), 2005, 41 (9), 563-578.
4. Nielsen LL, Young AA, Parkes DG. Pharmacology of Exenatide (synthetic Exendin-4), a potential therapeutic for improved glycemie control of type 2 diabetes[J]. Regul Pept, 2004, 117(2): 77-88.
5. Keating GM. Exenatide[J]. Drugs, 2005, 65(12), 1681-1695.
6. Kolterman OG, Buse JB, Fineman MS, et al. Synthetic Exendin-4 ( AC2993 ) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes[J]. J Clin Endocrinol Metab, 2003, 88(7), 3082-3089.
7. Briones M, Bajaj M. Exenatide, a GLP-I receptor agonist as novel therapy for type 2 diabetes mellitus[J]. Expert Opin Pharmacother , 2006, 7(8): 1055-1064.
8. Brubaker PL, Drucker DJ. Structure-function of the glucagon receptor family of G protein-coupled receptors[J]. the glucagon, GIP, GLP-I, and GLP-2 receptors[J]. Receptors Channels, 2002, 8(3-4): 179-188.
9. Stoffers DA, Desai BM, DeLeon DD, et al. Neonatal Exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat[J]. Diabetes, 2003, 52(3): 734-740.
10. Fineman MS, Bicsak TA, Shen LZ, et al. Effect on glycemic control of synthetic Exendin-4 (AC2993) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes[J]. Diabetes Care, 2003, 26(8): 2370-2377.
11. Abraham EJ, Leech CA, Lin JC, et al. Insulinotropic hormone glucagon like peptide 1 differentiation of human pancreatic islet derived progenitor cells into insulin producing Cells[J]. Endocrinology, 2002, 143(8): 3152-3161.
12. Li Y., Hansotia T., Yusta B., et al. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis [J]. J Biol Chem ,2003, 278(1): 471-478.
13. Estall JL, Drucker DJ. Glucagon and glucagon-like Peptide receptors as drug targets[J]. Curr Pharm Des ,2006, 12(14): 1731-1750.
14. Gallwitz B. Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus[J]. Treat Endocrinol, 2005, 4(6): 361-370.
15. Hui HX, Wright C., Perfetti R. Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-posi-tive pancreatic ductal cells into insulin-secreting Cells[J]. Diabetes, 2001, 50(4): 785-796.
16. Leech CA, Holz GG, Chepurny O, et al. Expression of cAMPregulated guanine nucleotide exchange factors in pancreatic beta-cells[J]. Biochem Biophys Res Commun , 2000, 278(1): 44-47.
17. Baggio LL, Drucker DJ. Therapeutic approaches to preserve islet mass in type 2 diabetes[J]. Amiu Rev Med, 2006, 57, 265-281.
18. Kathleen D, John B. Glucagon-like peptide 1-based therapies for type 2 diabetes, a focus on Exenatide [ J ]. Clinical Diabetes, 2005, 23(2): 56-62.
19. Gedulin BR, Nikoulina SE, Smith PA. et al. Exenatide (Exendin-4) improves insulin sensitivity and β-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight [J]. Endocrinology, 2005, 146(4): 2 069 - 2 076.
20. Idris I. Patiag D, Gray S. et al. Exendin-4 increases insulin sensitivity via a PI-3-kinase-dependent mechanism, contrasting effects of GLP1[J]. Biochem Pharmacol, 2002, 63(5): 993-996.
21. Terri P, Patrie N. Larry S, et al. Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study[J]. Diabetes Technology and Therapeutics, 2005, 7(3): 467-477.
22. Szayna M, Doyle ME, Betkey JA, et al. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats [J]. Endocrinology, 2000, 141(6): 1936-1941.
23. Kolterman OG, Buse JB, Fineman MS, et al. Synthetic Exendin-4 (AC2993) Signify cantly reduces post-prandial and fasting plasma glucose insubjects with type 2 diabetes[J]. Clin Endocrinol Metab, 2003, 88(7): 3082-3089.
24. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial[J]. Ann Inter Med, 2005, 143 (8), 559-569.
25. Triplitt C, Chiquette E. Exenatide, from the Gila monster to the pharmacy[J]. J Am Pharm Assoc, 2006, 46(1): 44-52.
26. Bray GM. Exenatide[J]. Am J Health Syst Pharm , 2006, 63 (5): 411-418.